Key Highlights – CB5138-3
We are developing CB5138-3 to treat IPF and are evaluating the impact of CB5138 Analogs on a variety of other chronic fibrotic conditions. CB5138-3 has been shown to:
- Decrease expression of fibrosis biomarkers in co-cultures of lung cells and fibroblasts.*
- Decrease Ashcroft fibrosis score and lymphocytes in lung fluid after 21 days in prophylactic mouse model.*
- Demonstrate positive effects on all study outcomes in a therapeutic mouse model, including significantly reduced lung fibrosis as evidenced by decreases in the Ashcroft Score, fibrosis-related changes in lung weight, collagen deposition in lung tissue and collagen secretion into lung fluid.
- Demonstrate significant reductions in lung fluid levels of a variety of pro-inflammatory cytokines and inflammatory cells in a therapeutic mouse model.
*This preclinical activity was demonstrated in earlier CB5138 Analogs